INTRODUCTION

Respiratory syncytial virus (RSV) is one of the most common causes of viral lower respiratory tract infection (LRTI) in children worldwide and
is associated with considerable morbidity and mortality [1] . LRTI was the leading cause of infectious disease hospitalizations among infants according to a recent analysis of hospital admissions in the United States (US) [2] . Globally, LRTI is the leading cause of death among post-neonatal infants (i.e., 28-364 days of age). In 2010, 20.1% of the 2 million global deaths among post-neonatal infants were caused by LRTI; malaria was the second most common cause, accounting for 11.8% of postneonatal mortality [3] . The most commonly identified pathogen of LRTI in post-neonatal infants is RSV [3] . These findings highlight the significance of the malaria parasite Plasmodium falciparum and RSV as the two most important pathogen-specific causes of global mortality in this age group [3] . In addition to severe acute disease, evidence also suggests that children who had severe RSV infection early in life are more likely to develop subsequent wheezing during early childhood [4] and hyperreactive airways and asthma later in life [5] .
RSV is a typically seasonal virus with outbreaks spanning from late autumn through early spring in temperate climates and throughout the rainy season in tropical climates. RSV is an extremely infectious virus, such that almost all children have contracted RSV by the age of 2 years [6] . Furthermore, reinfections are frequent because previous infection with RSV does not confer long-term immunity [7] . RSV disease manifestations in infants range from mild upper respiratory tract infection to respiratory failure. Certain high-risk groups, including premature infants; infants with underlying medical conditions such as chronic lung disease of prematurity (CLDP), also known as bronchopulmonary dysplasia (BPD); hemodynamically significant congenital heart disease (CHD); immunocompromised conditions; and severe neuromuscular disease, are more prone to serious disease due to RSV with higher hospitalization and mortality rates than those without these conditions [8, 9] .
RSV is classified in the Pneumovirus genus of the Paramyxoviridae family of RNA viruses.
RSV is an enveloped virus, containing a negative-sense, single-stranded RNA genome comprising *15,000 nucleotides that encode 11 viral proteins [10] . The antigenicity of RSV is determined by two transmembrane glycoproteins. The RSV G glycoprotein is responsible for viral attachment to cells, and the RSV F glycoprotein promotes fusion of viral and cell membranes [10, 11] . Both the G and F glycoproteins are targets for RSV-neutralizing antibodies. RSV is classified in A and B subgroups, based on antigenic differences in the G protein [12] .
The current goal of RSV vaccine development is the prevention of serious RSV disease in the population at highest risk, i.e., young infants [13] . In the absence of an effective, curative treatment for RSV infection [13] , disease management is guided by the severity of respiratory distress and primarily involves supportive strategies such as hydration and oxygenation [6, 14] . An effective vaccine against RSV would be expected to decrease the global health burden and is urgently needed; however, one does not currently exist owing to the complexity and inherent challenges of RSV vaccine development. For example, neonates at risk for developing RSV disease have not been able to mount a strong immune response following administration of vaccines in development.
Strategies for vaccinating pregnant women have been proposed with the intent of maternal transfer of anti-RSV antibodies to the fetus [13] . However, this approach may not provide adequate protection for very premature infants, who may not benefit from immunity afforded by maternal immunization because transplacental transport of antibodies occurs during the third trimester [15] . Efficacy was not demonstrated in a series of trials in the 1960s that evaluated a formalin-inactivated whole virus RSV vaccine.
Ironically, respiratory disease from natural RSV infection was more severe in children who received the experimental vaccine compared with children who did not receive the vaccine [16] [17] [18] . Moreover, in 1 trial in which 31 infants 2-7 months of age received C1 injection of an experimental antigenic inactivated RSV vaccine, 2 deaths were attributed to the exaggerated clinical course of disease during RSV infection and were deemed to be associated with the vaccine [17] . Although the biologic cause leading to this phenomenon was never definitively determined, these discouraging results led to a more measured and Retrospective studies, epidemiologic studies, case reports, letters, comments, editorials, reviews, and meta-analyses were excluded from the systematic review. Results from the literature search and cross-referenced publications found from systematic reviews or meta-analyses that appeared to meet these selection criteria were independently reviewed at the full-text level by the same three authors;
any disagreements over whether to include a study in the systematic review were resolved by discussion among the authors.
Data Analyses
A meta-analysis of the primary outcome of RSV- 
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RESULTS
A total of 347 publications were retrieved from the literature search and reviewed at the abstract level (Fig. 1) Table 1 ).
The Cardiac trial was conducted over 4 consecutive seasons from 1998 to 2002 in a total of 1,287 children B24 months of age with hemodynamically significant CHD in the US, Canada, Sweden, Germany, France, the UK, and Poland [23] . In this trial, palivizumab reduced RSV-associated hospitalization by 45% in children with hemodynamically significant CHD from an incidence of 9.7% (63/648) in children receiving placebo versus 5.3% (34/639) in children receiving palivizumab (Table 1 ; Fig. 2 ) [23] . Although the Cardiac study was not powered for subgroup analyses, there were reductions in RSV-related hospitalization rates in both cyanotic and acyanotic children (Table 1 GA [30] . In 429 preterm infants born at 33-35 weeks GA without underlying health conditions, the incidence of RSV-associated hospitalization was reduced by 82%, from an incidence of 5.1% in those receiving placebo (11/ 215) versus 0.9% in those receiving palivizumab (2/214; P = 0.01; Table 1 ) [30] . In addition, RSV infection requiring medical attention but not Appendix Table A1 BPD Bronchopulmonary dysplasia, CHD hemodynamically significant congenital heart disease, CLDP chronic lung disease of prematurity,
NA not available, RSV respiratory syncytial virus hospitalization was also significantly reduced by 81%, from an incidence of 4.7% in recipients of placebo (10/215) versus 0.9% in recipients of palivizumab (2/214; P = 0.02) [30] .
More recently, Tavsu et al. [31] conducted a study from 2009 to 2011 in 80 infants with a GA of \32 weeks in Turkey. These infants were randomized to receive prophylaxis with palivizumab (study group, n = 39) or no prophylaxis (control group, n = 41). The incidence of RSV-related hospitalization was significantly lower in the study group than the Fig. 2 RSV-related hospitalization rates in the large randomized controlled trials: a IMpact-RSV [24] , b Carbonell-Estrany et al. [70] , c MAKI [30] , d Tavsu et al. [31] , e Cardiac [23] , and f Feltes et al. [71] studies. Relative reduction rate compared with placebo is shown as ;%. Asterisk indicates without BPD/CLDP. BPD Bronchopulmonary dysplasia, CHD hemodynamically significant congenital heart disease, CLDP chronic lung disease of prematurity, GA gestational age, mo months, RSV respiratory syncytial virus, wk weeks, y years control group both in the year of prophylaxis and the following year (0% vs. 24 Table 2 ).
Many guidelines are aligned with the licensed indications of palivizumab and recommend that children with BPD requiring medical intervention at the onset of the RSV season receive prophylaxis up to the age of 24 months at the start of the RSV season (US, UK, Canada, Spain, and Germany) [33] [34] [35] [36] [37] .
Therefore, some children with severe BPD will receive prophylaxis for more than one RSV season. A multicenter, open-label study was conducted in 7 European countries and Canada in 134 children \2 years old at risk for serious RSV infection, primarily because of BPD [38] .
Seventy-one subjects without previous palivizumab exposure (mean age 8 months) and 63 subjects exposed to palivizumab during the previous season (mean age 16 months) received prophylaxis with palivizumab during the 1999-2000 RSV season. Five subjects (3.7%) were hospitalized for RSV-related respiratory illness overall, with no differences in incidence observed between the first-season exposure (1 [1.4%]) and second-season exposure subjects (4 [6.3%]; P = 0.187; Table 2 ) [38] . This study (Table 2 ). This RSV hospitalization rate is comparable to the incidence observed in the IMpact-RSV study [24] .
Prior to palivizumab approval in the Russian Federation, a multicenter, prospective, openlabel, non-comparative clinical study (ClinicalTrials.gov #NCT01006629) was conducted in high-risk children [40] . The study included children at high risk of serious RSV disease, defined as infants born at B35 weeks GA who were B6 months old at enrollment or children B24 months old with a clinical diagnosis of BPD and/or Table 3 ). The highest rate (7.6%) was observed in a French registry [42] , whereas the rate ranged from 0.8% to 3.95% in the other observational studies/registries [26, 41, [43] [44] [45] [46] . The higher RSV hospitalization rate observed in the French registry may have been driven by enrollment of a very-high-risk population where 88% of subjects in the cohort had a GA B32 weeks, 52% were children born before 28 weeks GA, and the rate of BPD was 81%. In comparison, the rate of BPD among children enrolled in the IMpact-RSV study was 50% [24, 42] . In general, RSV-related hospitalization rates were similar for palivizumab recipients in the observational studies/registries and in the randomized placebo-controlled trials.
Secondary Outcomes: RSV
Hospitalization-Related Endpoints
Although prophylaxis with palivizumab reduces the incidence of RSV-related hospitalizations, some children still develop breakthrough disease and require hospitalization. Tables 1, 2 and 3 illustrate the effect of palivizumab prophylaxis on RSV hospitalization-related endpoints. These are important surrogate markers of disease severity and include duration of RSV-related hospitalization, intensive care unit (ICU) admission, oxygen supplementation, and mechanical ventilation.
In the IMpact-RSV study, children with BPD or a history of prematurity randomized to receive prophylaxis with palivizumab spent significantly fewer days in the hospital and required fewer days of supplemental oxygen during RSV hospitalization compared with children randomized to receive placebo (all P\0.001; Table 1 ) [24] . The overall requirement for ICU admission and/or mechanical ventilation was low and was influenced by a small number of children with complex underlying disease. Differences in the incidence of and days on mechanical ventilation did not differ significantly between groups [24] . Children with hemodynamically significant CHD receiving palivizumab prophylaxis also had significantly fewer days of RSV-related hospitalization (P = 0.003) and significantly fewer days with increased oxygen requirement compared with children receiving placebo (P = 0.014; Table 1 ) [23] . Other secondary efficacy endpoints, including incidence and days in the ICU and days on mechanical ventilation were not significant but did exhibit trends favoring palivizumab over placebo.
The results of the RSV hospitalization-related outcomes from the non-comparative trials and (Table 3) conducted in Spain and the US [27, 28, 45] compared with 0.3-1.3% in the RCTs (Table 1 ).
In the only observational study to include case controls, there was a statistically significant reduction in RSV hospitalization duration and numerical decreases in the percentage of subjects requiring ICU admission or mechanical ventilation in Spanish subjects who received prophylaxis with palivizumab compared with those who did not receive prophylaxis [45] .
Safety and Immunogenicity
The safety data for palivizumab was first established in 2,789 infants enrolled in the two registrational randomized placebocontrolled trials (Table 4) [23, 24] . In the IMpact-RSV trial, there was no difference in the placebo and palivizumab groups in the number of children who had AEs that were judged to be related to the study drug by the blinded investigator (10% vs. 11%) [24] . Study subjects rarely discontinued prophylaxis due to palivizumab-related AEs (0.3%), and the incidence of related AEs did not differ significantly between the placebo and palivizumab groups. Similar safety findings were demonstrated in the Cardiac study [23] .
The proportion of children with AEs judged by the blinded investigator to be related to the study drug was similar between the placebo and palivizumab groups (6.9% vs. 7.2%). No child had the study drug discontinued for a related AE, and the incidence of related SAEs was low and similar in the placebo and palivizumab groups (0.5% vs. 0%).
Given that palivizumab has been in clinical use for 16 years, follow-up clinical trials, outcome data from several international registries and post-marketing experience are consistent with the initial safety profile.
Uncontrolled trial (Table 5 ) and observational/ registry data (Appendix Table A2 Detailed characteristics of these studies are presented in Appendix Table A1 AE Adverse event, BPD bronchopulmonary dysplasia, CHD congenital heart disease, CLDP chronic lung disease of prematurity, response to the monoclonal antibody. In the IMpact-RSV trial, anti-palivizumab antibodies were assessed before the first and last palivizumab injections and in a randomized manner before the second, third, or fourth injection [24] . In the placebo and palivizumab groups, titers [1:40 were detected in 2.8% and 1.2% of subjects, respectively. These elevations generally occurred at single time points and were not associated with low palivizumab concentrations or increased AEs. In a French study conducted to assess the incidence of anti-palivizumab antibodies and clinical AEs in children prophylaxed with palivizumab for a first (no previous palivizumab exposure) versus a second RSV season, similar serum concentrations of palivizumab were observed for both first-season and second-season subjects, and none had a significant antipalivizumab antibody response, defined as a titer of C1:80 occurring at any time during the study [38] . 
Current Issues in RSV Immunoprophylaxis
Strategies for diminishing the health care burden from RSV infections include appropriate and targeted prophylaxis in children at high risk of severe RSV disease. More research is needed to examine the impact of RSV infection on subsequent morbidity and mortality, to understand the full impact and burden of RSV infections, and to clarify additional health benefits and the value of prophylaxis. There is evidence suggesting that palivizumab is associated with reduced infant all-cause mortality [63, 64] . In addition, prophylaxis with palivizumab has been associated with a reduction in longterm respiratory morbidity of severe RSV infection, such as recurrent wheeze [65, 66] .
In a placebo-controlled trial in otherwise healthy preterm infants of 33-35 weeks GA, prophylaxis with palivizumab led to a 61% reduction in wheezing days that was maintained beyond the end of therapy and throughout the infants' first year of life (P\0.05) [30] . A prospective analysis of clinical trial data in preterm children B35 weeks GA reported that palivizumab exposure may decrease the incidence of subsequent asthma-like symptoms [65] and provide a protective effect on recurrent wheezing in prophylaxed children without a family history of atopy through 24 months compared with matched controls [67] . Finally, a prospective Japanese study in preterm children born at 33-35 weeks GA found a lower incidence of recurrent wheezing during the first 3 years of life after palivizumab exposure [66] . When considering the impact of palivizumab on long-term respiratory effects, it is important to note that the majority of the evidence is from non- have been demonstrated to confer resistance to palivizumab [68] . The rate of palivizumabresistant mutations is low in both immunoprophylaxis-naïve patients (\1%) [68] and in patients experiencing breakthrough RSV disease while taking palivizumab (6.3%) [22] . 
Limitations
There are several limitations of this systematic review that must be considered. Although multiple studies and post-marketing experience involving thousands of high-risk infants indicate that palivizumab reduces overall hospitalization rates due to RSV, it is important to note there are few RCTs and the majority of the evidence is based on prospective observational studies/registries. As the observational studies/registries do not involve a control arm, they cannot definitively evaluate the true impact of RSV prophylaxis as documented in the placebo-controlled randomized trials [23, 24] . In addition, the populations in these cohorts may be variable, as enrollment is based on country-specific pediatric prophylaxis guidelines and the data reflect the way in which health care providers use palivizumab in the real world. Finally, RSV hospitalization detection rates are influenced by the hospitalization/ICU threshold changes over time, changes in bronchiolitis diagnosis over time, the type of samples collected, and the type of tests conducted. 
